Evidence map›Paper›PMID 40620658›Full record

ArticleBlood immunology & cellular therapy2025

Combining antigen specific T-cells with T-cell engager therapy induces a molecular signature that favors T-cell fitness.

Manpreet Bariana, Sidharth Anand, Mark Batistick, Elena Cassella, Shaina A Anuncio, Ariel Aptekmann, David S Siegel, Mathias Oelke, Sojung Kim, Ruipeng Wang and 2 more

Abstract read
In one paragraph

Article in Blood immunology & cellular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Manpreet BarianaCenter for Discovery and Innovation, Hackensack Meridian Health.
Sidharth AnandHackensack Meridian School of Medicine.
Mark BatistickStony Brook University Hospital.
Elena CassellaCenter for Discovery and Innovation, Hackensack Meridian Health.
Shaina A AnuncioCenter for Discovery and Innovation, Hackensack Meridian Health.
Ariel AptekmannCenter for Discovery and Innovation, Hackensack Meridian Health.
David S SiegelMultiple Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center.
Mathias OelkeNexImmune Inc.
Sojung KimNexImmune Inc.
Ruipeng WangNexImmune Inc.
Jack A RaghebNexImmune Inc.
Johannes L ZakrzewskiCenter for Discovery and Innovation, Hackensack Meridian Health.

Funding

Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cellsR37CA250661 · NCI · HACKENSACK UNIVERSITY MEDICAL CENTER · PI Johannes Zakrzewski · 2022 to 2026
$2.7M
NCI NIH HHS R37 CA250661
6 · The paper itself

Abstract

Both adoptive cellular therapy with tumor antigen-specific T-cells and redirection of endogenous T-cells with bispecific tumor-specific T-cell engaging antibodies rely on CD8

Identifiers

PMID40620658
PMCPMC12228535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.